Trial Profile

Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ezurpimtrostat (Primary) ; Trametinib (Primary)
Indications Cholangiocarcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors Genfit

Most Recent Events

13 Nov 2024 According to a GENFIT media release, Final data is expected by the end of 2025.
04 Apr 2024 According to a GENFIT media release, preliminary data from Phase 1b is targeted by the end of 2024.
08 Jan 2024 Planned End Date changed from 1 Nov 2026 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com